{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:57:50Z","timestamp":1715986670530},"reference-count":52,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"unrestricted grant from PamGene"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.2217\/pgs.10.187","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T13:15:14Z","timestamp":1301490914000},"page":"411-421","source":"Crossref","is-referenced-by-count":12,"title":["Application of Cost\u2013Effectiveness Analysis to Demonstrate the Potential value of Companion Diagnostics in Chronic Myeloid Leukemia"],"prefix":"10.1080","volume":"12","author":[{"given":"Jennifer G","family":"Gaultney","sequence":"first","affiliation":[{"name":"Institute for Medical Technology Assessment\/Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands"},{"name":"Tel.:  Fax:"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Sanhueza","sequence":"additional","affiliation":[{"name":"Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J","family":"Janssen","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K","family":"Redekop","sequence":"additional","affiliation":[{"name":"Institute for Medical Technology Assessment\/Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A","family":"Uyl-de Groot","sequence":"additional","affiliation":[{"name":"Institute for Medical Technology Assessment\/Institute of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1234"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100319"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000189625"},{"key":"e_1_3_3_3_4_1","unstructured":"Drummond MF SculpherMJ TorranceGW O\u2018BrienB StoddartGL: Methods for the Economic Evaluation of Health Care Programmes 3rd Edition. Oxford Medical Publications Oxford UK (2005)."},{"key":"e_1_3_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105805"},{"issue":"5","key":"e_1_3_3_3_6_1","first-page":"313","article-title":"Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.","volume":"11","author":"Hornberger J","year":"2005","unstructured":"Hornberger J , CoslerLE, LymanGH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.Am. J. Manag. Care11(5) , 313\u2013324 (2005).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.5.8.1139"},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826070-00005"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3343"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601151"},{"issue":"30","key":"e_1_3_3_3_12_1","first-page":"1460","article-title":"[Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment].","volume":"147","author":"Groot MT","year":"2003","unstructured":"Groot MT , OssenkoppeleGJ, KramerMH et al.: [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment].Ned. Tijdschr. Geneeskd.147(30) , 1460\u20131465 (2003).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta8280"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20694"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.007"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.3.325.61593"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0371"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.531"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_3_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-12-200612190-00008"},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110189"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Boender P JanssenJ SmitL et al.: Application of kinase activity profiles to predict upcoming TKI resistance in CML-patients. Presented at: the American Society of Hematology Annual Meeting. 4\u20137 December FL USA. 116(21) (2010) (Abstract 3425).","DOI":"10.1182\/blood.V116.21.3425.3425"},{"key":"e_1_3_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.04.036"},{"key":"e_1_3_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.10566"},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_3_3_3_28_1","unstructured":"Lowenberg B OssenkoppeleGJ de Witte T Boogaerts MA: Chronic Myeloid Leukemia. In: Handboek Hematologie. De Tijdstroom Utrecht The Netherlands 489\u2013500 (2008)."},{"issue":"11","key":"e_1_3_3_3_29_1","first-page":"2170","volume":"108","author":"Giles F","year":"2006","unstructured":"Giles F , le Coutre P, Bhalla K et al.: A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. ASH Annual Meeting Abstracts108(11) , 2170 (2006).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035493"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141580"},{"issue":"4","key":"e_1_3_3_3_32_1","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"91","author":"Gratwohl A","year":"2006","unstructured":"Gratwohl A , BrandR, ApperleyJ et al.: Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).Haematologica91(4) , 513\u2013521 (2006).","journal-title":"Haematologica"},{"key":"e_1_3_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0248"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_3_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_3_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200422080-00001"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000189627"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0901355"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.6.853"},{"key":"e_1_3_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.10.1.149"},{"key":"e_1_3_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462308080604"},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.2217\/17410541.6.1.93"},{"key":"e_1_3_3_4_2_1","unstructured":"NICE: Evidence to support chronic myeloid leukaemia drugs \u2018very poor\u2018 (February 2010) www.nice.org.uk\/newsroom\/news"},{"key":"e_1_3_3_4_3_1","unstructured":"Dutch Healthcare Insurance Board: Guidelines for Pharmacoeconomic Research (in dutch). Diemen (March 2006) www.cvz.nl\/binaries\/live\/cvzinternet\/hst_content\/nl\/documenten\/rubriek+zorgpakket\/cfh\/richtlijnen+farmaco-economisch+onderzoek.pdf (Accessed 1December2008)"},{"key":"e_1_3_3_4_4_1","unstructured":"Dutch Healthcare Insurance Board: Farmacotherapeutisch Kompas. www.fk.cvz.nl (Accessed 1December2008)"},{"key":"e_1_3_3_4_5_1","unstructured":"Nederlandse Zorgautoriteit: Search program for DBC amounts and other amounts due to specialist medical care visits for healthcare www.ctg.bit-ic.nl\/Nzatarieven\/top.do (Accessed 1December2008)"},{"key":"e_1_3_3_4_6_1","unstructured":"Centraal Bureau voor de Statistiek: Statline database for all statistics relevant to the Netherlands www.statline.cbs.nl (Accessed 14November2010)"},{"key":"e_1_3_3_4_7_1","unstructured":"UK Secretary of State for Health: Government Response to the House of Lords: Science and Technology Committee Inquiry into Genomic Medicine (December 2009) www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_110005.pdf (Accessed 13July2010)"},{"key":"e_1_3_3_4_8_1","unstructured":"US Department of Health and Human Services: Federal Coordinating Council for Comparative Effectiveness Research: Report to the President and the Congress www.hhs.gov\/recovery\/programs\/cer\/cerannualrpt.pdf (Accessed 13July2010)"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs.10.187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:30:55Z","timestamp":1715949055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs.10.187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.2217\/pgs.10.187"],"URL":"https:\/\/doi.org\/10.2217\/pgs.10.187","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}